Pozen (POZN) -24.7% premarket after the biotech company discloses the FDA requested additional data for its PA32540 fixed-dose "safer aspirin" product which may delay submission of its new drug application
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/